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ABSTRACT
Introduction Cardiac rehabilitation (CR) is offered to 
reduce the risk of further cardiac events and to improve 
patients’ health and quality of life following a cardiac 
event. Psychological care is a common component of 
CR as symptoms of depression and/or anxiety are more 
prevalent in this population, however evidence for the 
cost- effectiveness of current interventions is limited. 
Metacognitive therapy (MCT), is a recent treatment 
development that is effective in treating anxiety and 
depression in mental health settings and is being 
evaluated in CR patients. This protocol describes the 
planned approach to the economic evaluation of MCT for 
CR patients.
Methods and analysis The economic evaluation 
work will consist of a within- trial analysis and an 
economic model. The PATHWAY Group MCT study has 
been prospectively designed to collect comprehensive 
self- reported resource use and health outcome data, 
including the EQ- 5D, within a randomised controlled trial 
study design (UK Clinical Trials Gateway). A within- trial 
economic evaluation and economic model will compare 
the cost- effectiveness of MCT plus usual care (UC) to 
UC, from a health and social care perspective in the UK. 
The within- trial analysis will use intention- to- treat and 
estimate total costs and quality- adjusted life- years (QALYs) 
for the trial follow- up. Single imputation will be used to 
impute missing baseline variables. Multiple imputation 
will be used to impute values missing at follow- up. Items 
of resource use will be multiplied by published national 
healthcare costs. Regression analysis will be used to 
estimate net costs and net QALYs and these estimates 
will be bootstrapped to generate 10 000 net pairs of costs 
and QALYs to inform the probability of cost- effectiveness. 
A decision analytical economic model will be developed 
to synthesise trial data with the published literature over 
a longer time frame. Sensitivity analysis will explore 
uncertainty. Guidance of the methods for economic models 
will be followed and dissemination will adhere to reporting 
guidelines.
Ethics and dissemination The economic evaluation 
includes a within- trial analysis. The trial which included 
the collection of this data was reviewed and approved 
by Ethics. Ethics approval was obtained by the Preston 
Research Ethics Committee (project ID 156862). The 
modelling analysis is not applicable for Ethics as it will 
use data from the trial (secondary analysis) and the 
published literature. Results of the main trial and economic 
evaluation will be published in the peer- reviewed National 
Institute for Health Research (NIHR) journals library 
(Programme Grants for Applied Research), submitted to 
a peer- reviewed journal and presented at appropriate 
conferences.
Trial registration number ISRCTN74643496; Pre-results.
INTRODUCTION
In the UK approximately 90 000 people 
start cardiac rehabilitation (CR) annually, 
receiving a supervised programme of care 
that aims to improve patients’ health and 
quality of life.1 The population offered CR is 
variable; the British Association for Cardiovas-
cular Prevention and Rehabilitation propose 
three groups of priority, including acute coro-
nary syndrome, coronary revascularisation 
and/or heart failure, with further groups who 
should be offered CR if possible (including 
stable angina among others).2 The greatest 
number of attendees of CR in the UK come 
from populations with myocardial infarction, 
percutaneous coronary intervention, coro-
nary artery bypass graft and heart failure.1 
Strengths and limitations of this study
 Ź A prospectively designed within- trial economic eval-
uation alongside a randomised controlled trial, with 
comprehensive data collection.
 Ź Supplemented by an exploratory decision analytical 
model to assess cost- effectiveness over a longer 
time horizon.
 Ź Comprehensive sensitivity analysis will be used to 
explore a range of alternative measures of health 
beneits, impact of assumptions and time horizons.
 Ź Data limitations, such as the trial time frame, are 
likely to affect the plausibility of long- term results.
 Ź Issues with generalisability due to variations across 
cardiac services and populations entering cardiac 
rehabilitation.
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The reported benefits of CR include reduced mortality, 
reduced hospital admissions, improvements in patient 
cardiovascular risk profiles and improved psycholog-
ical well- being and quality of life.3 Around 50% of those 
offered CR attend.1
The latest figures suggest that in the UK around 18% 
and 28% of patients initiating CR have borderline or 
clinical depression and anxiety, respectively.4 Rehabili-
tation programmes vary, most frequently including life-
style risk factor management (eg, physical exercises) 
and health behaviour change and education.3 Guide-
lines also recommend that a psychological component is 
included in CR care.3 Despite this, current interventions 
(including pharmacological and psychosocial interven-
tions) have been shown to have limited effectiveness in 
this group.5 Psychological components of CR have been 
less frequently analysed in cost- effectiveness evalua-
tions and results of cost- effectiveness studies are varied.6 
Research to determine whether psychological therapy is 
effective and cost- effective in CR is a priority, given recent 
calls for closer integration of psychological and physical 
health outcomes.7
Metacognitive therapy (MCT) may be well- suited to 
the needs of CR patients; it is based on the metacognitive 
model, which proposes that a thinking style dominated 
by rumination, worry and threat monitoring maintains 
emotional distress.8–10 MCT is highly effective at reducing 
this thinking style and alleviating symptoms of depression 
and/or anxiety in mental health settings and may there-
fore have the potential to improve health in the CR popu-
lation.5 11 12 There are no existing published economic 
evaluations of MCT.
The PATHWAY Group MCT multicentre, single- blind, 
randomised controlled trial aims to evaluate the effec-
tiveness and cost- effectiveness of group- based meta-
cognitive therapy for CR patients with elevated anxiety 
and/or depressive symptoms.5 Details of the main trial 
study protocol are available elsewhere.5 In brief, partic-
ipants were recruited from patients with heart disease 
and referred for CR, in five UK National Health Service 
(NHS) Trusts. Trial participants had to meet CR eligi-
bility criteria, score 8 or more on either the anxiety 
and/or depression subscale of the Hospital Anxiety and 
Depression Scale (HADS), be aged 18 years old or more 
and able to read, understand and complete question-
naires in English. Patients who gave informed consent 
to participate in the trial completed baseline assessments 
and were randomised via telephone link to Manchester 
Clinical Trials Unit. Participants were allocated to the 
intervention/comparator arms in a 1:1 ratio via a minimi-
sation algorithm (incorporating a random component) 
to maximise balance between the two arms on gender, 
HADS score and hospital site. Participants randomised 
to the intervention arm received 6 weekly sessions of 
group- based metacognitive therapy delivered by either 
CR professionals or research nurses. The intervention 
and control groups were both offered in the usual CR 
programme within their Trust. The primary outcome is 
severity of anxiety and depressive symptoms at 4- month 
follow- up measured by the HADS total score.13 Secondary 
outcomes are severity of anxiety/depression at 12- month 
follow- up, health status, severity of post- traumatic stress 
symptoms, strength of metacognitive beliefs and service 
use at 4- month and 12- month follow- up. The PATHWAY 
Group MCT trial is part of a wider NIHR (National Insti-
tute for Health Research) programme grant for applied 
research, which began in August 2014 and with an end 
date of February 2021.
The aim of the economic evaluation component of 
the PATHWAY Group MCT trial is to estimate the cost- 
effectiveness of the addition of MCT intervention to CR 
for patients with elevated anxiety and/or depression 
symptoms, in a UK setting from a health and social care 
perspective. This will consist of a within trial analysis using 
patient- level data collected during baseline and follow- up 
study time points, and an economic model synthesising 
data from the trial and wider literature.
METHODS AND ANALYSIS
The economic evaluation of group MCT in CR will 
comprise of two analyses; a within- trial economic analysis 
prospectively designed to assess cost- effectiveness for the 
duration of the trial (12 months) and an economic model 
to explore the potential longer- term cost- effectiveness of 
MCT in this population and in different populations and 
settings.
Both analyses will use a cost- effectiveness acceptability 
analysis to assess the incremental cost- effectiveness of 
the addition of MCT intervention to the CR for patients 
with elevated anxiety and/or depression symptoms. The 
intervention is group- based MCT plus usual CR, and the 
comparator is usual CR alone. The perspective for the 
primary analysis (trial and model) is health (NHS) and 
social care service providers (costs) and CR participants 
(health benefits), which is the perspective recommended 
by National Institute for Health and Care Excellence 
(NICE).14 Note that social care in the UK is delivered 
by a range of providers (public sector, commercial and 
voluntary) and encompasses a range of social support 
services.15 The work will conform to the NICE recom-
mended methods and will be reported in accordance with 
the Consolidated Health Economic Evaluation Reporting 
(CHEERS) statement.14 16
Patient and public involvement
The patient and public involvement (PPI) group from 
the group MCT trial will be presented with the findings 
of the economic evaluation and consulted about possible 
dissemination activities that target patient groups.
Within-trial analysis
The analysis will use individual patient- level service use 
and health benefit data from all participants recruited and 
allocated to a management arm in the PATHWAY Group 
MCT trial (n=332). The trial opened for recruitment in 
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July 2015 and closed in January 2018, follow- up finished 
in February 2019. The economic analysis of trial data will 
begin in April 2020 and will complete by September 2020. 
The analysis will compare the addition of group- based 
MCT to usual CR versus usual CR alone (standard prac-
tice) for individuals with elevated symptoms of depression 
and/or anxiety. The study sample for the economic evalu-
ation is all participants randomised to receive the group- 
based MCT plus usual CR, or usual CR only. In brief, 
participants were people eligible and offered (referred 
to) CR as per NHS trust protocol, with a HADS score of 8 
or more on the anxiety and/or depression subscale. The 
intervention, usual care and participant inclusion and 
exclusion criteria are summarised and described in detail 
in the trial protocol.5 Usual CR (dependant on NHS site) 
includes varying degrees, psychological interventions to 
address distress such as relaxation, stress management 
and some cognitive challenging.
The time horizon of the within- trial primary cost- 
effectiveness analysis will be 12 months, to incorporate 
sufficient time for any impact of MCT on service use, 
subsequent costs and health benefit. This differs to the 
primary clinical effectiveness time horizon, which will 
be 4 months (note, a sensitivity analysis will look at cost- 
effectiveness at 4- month follow- up).5
Outcomes
The measure of health benefit for the primary analysis 
will be the quality- adjusted life- year (QALY). This will 
be estimated from the EQ- 5D- 5L health status measure 
completed at baseline and 4- month and 12- month 
follow- up. The EQ- 5D is a validated, generic health status 
measure, allowing for the comparison of health bene-
fits across different disease areas. The EQ- 5D has been 
shown to be a valid and responsive measure of health in 
CR patients.17 Furthermore, the QALY and the EQ- 5D are 
the measures recommended for economic evaluations by 
NICE.18
The EQ- 5D- 5L captures the following five domains 
of health status: mobility, self- care, usual activity, pain/
distress and anxiety/depression. Each domain is rated 
on a 5- point scale of levels: no problems, slight problems, 
some problems, severe problems or unable to do activity. 
Resulting health status profiles will be converted to utility 
values using the published utility tariffs and methods 
recommended by NICE at the time of analysis. An 
EQ- 5D- 5L valuation set is available that reflects the pref-
erences of members of the public in England for health 
states defined by the EQ- 5D- 5L.19 However, concerns have 
been raised during the quality assurance of this value set 
and currently, NICE recommend that the crosswalk algo-
rithm used to map from the EQ- 5D- 3L to the EQ- 5D- 5L 
continues to be used.20 The economic evaluation will use 
the value set recommended by NICE at the time of anal-
ysis. The use of alternative value sets will be investigated 
in the sensitivity analysis.
Total QALYs will be estimated as follows:
 2"-: 
∑ 	[6J  6J

]
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 − UJ
 
Here, U=utility value and t=time between assessments. 
The time between assessments is the time from baseline 
data collection to follow- up.
Resource use and costs
Direct costs will be estimated for the primary analysis. 
Service use included in the economic evaluation is listed 
in table 1. With the exception of the intervention and 
usual care cardiac rehabilitation, data on the health-
care resources used for each participant were collected 
from an economic patient questionnaire at baseline and 
follow- up (4 and 12 months). The questionnaire was 
adapted from surveys used by the authors in previous 
trials.21–24 The changes to the questionnaire were devel-
oped with the service user group and the clinical experts 
in the research team. The questionnaire was pilot tested 
before use. At baseline this is completed by the partici-
pant with assistance from a researcher. This means partic-
ipants have experience of completing it once with help 
before they need to complete it unassisted. At follow- up 
participants complete the questionnaire on their own 
but were aware a researcher could help them complete 
the questionnaire if needed. A copy of the questionnaire 
is provided in the online supplementary material and 
has been uploaded to the Database of Instruments for 
Resource Use Measurement (DIRUM).25 The question-
naire asks patients to report service use for the follow- up 
period (time since the last questionnaire or 3 months at 
Table 1 Economic evaluation service use measures
Service type Unit measure
NHS healthcare use (collected by a self- report economic 
patient questionnaire)
Hospital inpatient Days per stay
Hospital day Number of visits
Hospital outpatient Number of visits
Accident and emergency Number of visits
Primary care* Number of visits
Community care† Number of visits
Metacognitive therapy (collected by the trial team)
Staff time (cardiac rehabilitation 
nurse, cardiac nurse, physiotherapist 
or occupational therapist)
Number of hours
Paper manual By unit
CD exercise By unit
Cardiac rehabilitation attendance (collected by the trial 
team)
Exercise cardiac rehabilitation Number of attendances
Education cardiac rehabilitation Number of attendances
*Examples include general practitioner.
†Examples include community- based mental healthcare and 
social support.
CD, compact disk; NHS, National Health Service.
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baseline) and for the last month. If a participant struggles 
to recall service use for the full follow- up but knows the 
last month, this is included to help prompt the partici-
pant. For the primary analysis, participants with 1- month 
but not the full assessment period service use data will be 
treated as having missing data. The missing data will be 
imputed using the multiple imputation process defined 
for all participants with missing data. Two sensitivity anal-
yses will explore the impact of using the 1- month recall 
data (see table 2).
Note that from the reported service use, psychological 
treatment outside of cardiac rehabilitation and MCT will 
also be costed. MCT attendance data collected during the 
trial by the research team will be used to estimate a per 
participant cost for the MCT intervention. In the primary 
analysis, this will include staff costs and the cost of mate-
rials. The average group size from the trial will be used to 
calculate a cost per session per participant, which will be 
multiplied by the number of sessions attended by each 
participant. Staff time to deliver MCT and attendances 
at cardiac rehabilitation will be collected by the research 
team.
The unit costs of NHS and social care services will be 
derived from national average unit cost data. These unit 
costs are published annually in the NHS reference costs 
database, and in the Unit Costs of Health and Social 
Care document published by the Personal Social Services 
Research Unit, University of Kent. The price year for all 
costs will reflect the most recent unit costs at the time of 
analysis. The total direct costs of service use for each trial 
arm (including MCT and cardiac rehabilitation) will be 
estimated by summing the costs of each resource by the 
reported use to provide health and social care.
Missing data
Analysis of the economic data will use an intention- to- 
treat approach that includes service use, cost and health 
benefit data for all services users, regardless of whether 
they completed the planned follow- up and all the 
measures used at assessment. It is highly likely that data 
will be missing, either from loss to follow- up or incom-
plete data collection.
Single imputation will be used to impute missing base-
line data. This simple approach is appropriate for base-
line data, although in reality this is unlikely to have a 
significant impact as participants who have missing data 
at baseline are less likely to have follow- up data.26 27 Base-
line variables are observed at entry to the trial and vary 
by the individual rather than random allocation to trial 
arms or values at follow- up. In contrast follow- up values 
for clinical and economic measures may be dependent 
on trial allocation and baseline. Accordingly, single impu-
tation for baseline measures of cost, utility and clinical 
indicators ensures the estimated values are indepen-
dent of treatment allocation and follow- up values. Single 
imputation is likely to be more efficient than multiple 
imputation. Multiple imputation (MI) will be used to 
impute missing follow- up data for costs and QALYs, which 
assumes that the data are missing at random (condi-
tional on observed responses to clinical and economic 
measures and baseline covariates); MI of both costs and 
QALYs is recognised as an appropriate approach to deal 
with missing observation and missing follow- up data.26 
Missing values will be imputed for each follow- up point. 
All missing follow- up cost and utility data will be assumed 
to be missing at random. To make best use of available 
data, we plan to impute costs by category (inpatient, 
outpatient and primary/community care) and utility by 
individual EQ- 5D domain (mobility, self- care, usual activi-
ties, pain/discomfort and anxiety/depression). A balance 
is required between including all items and the stability 
of the imputation model if there is a high level of missing 
data. The stability of the model reduces as the number 
of variables with missing data increases. If feasible, all 
individual items in each cost category will be included 
in the imputation model. Total costs and QALYs (base-
line to follow- up) will be generated using Stata passive 
estimation commands. The final imputation plan will be 
refined following a review of missing data (exploration 
of whether there are any patterns of missingness) and 
according to the patterns of service use and EQ- 5D data. 
Two sensitivity analyses will explore whether the results 
vary by approach taken to missing data. The first will use 
complete case analysis. The second will use a pattern 
mixture approach that assumes compliance and clinical 
outcomes are systematically worse in people with missing 
or with incomplete follow- up.26 28 The specification of the 
analysis will be finalised after review of the complete and 
missing data patterns and discussion with clinical experts 
about plausible assumptions. If appropriate this analysis 
will identify the threshold values of compliance and clin-
ical outcome that would lead to a change in conclusions 
about the relative cost- effectiveness of the within trial 
economic analysis.
Multiple imputations will be conducted in Stata V.15, 
using predictive mean matching and sequential chained 
equations. Regression models used to impute missing 
data will be based on key covariates associated with costs 
or health benefits. A long list of potential covariates was 
identified from a recent systematic review of economic 
evaluations in the population undergoing cardiac reha-
bilitation and the baseline data collected within this 
randomised controlled trial (see online supplementary 
material). Discussions with clinical experts in the team 
will be used to assess the relevance and logic of using these 
variables as covariates in our analysis. This approach will 
be supplemented with pooled descriptive analyses and 
regression analyses to identify the final set of covariates.6 
A list of potential covariates is included in the online 
supplementary material.
Primary analysis
Costs and health benefit for the primary and sensi-
tivity analyses will be estimated from baseline to end of 
12- month follow- up, to estimate the incremental cost- 
effectiveness of the addition of MCT intervention.
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Table 2 Within- trial sensitivity analysis
Assumptions/variables Changes Rationale
Missing data are assumed 
to be missing at random
 Ź Complete case analysis
 Ź Pattern mixture approach
The complete case analysis will use only the observed data and 
will provide insight to the result for the group of participants with 
complete follow- up and complete data (evaluable cohort).
The pattern mixture approach will assess the impact of assuming 
that compliance and clinical outcomes are systematically worse 
in people with missing or with incomplete follow- up. It will be 
assumed that these differences will also lead to systematic 
worse health beneits and higher costs for participants with 
missing data26 28
The results of the complete case and pattern mixture analyses 
will be compared with the primary analysis based on multiple 
imputed data sets to give an indication of how robust the cost- 
effectiveness estimate is to assumptions about missing data.
Use of 1- month recall data  Ź Assume that service use is equally 
distributed over the assessment 
period and that the 1- month data 
can be multiplied up to 4- month or 
8- month follow- up.
 Ź Add the 1- month cost estimates 
to the multiple imputation process, 
depending on the pattern of missing 
data and suficient participants 
with both 1- month and 4- month or 
8- month cost estimates.
The primary analysis treats the 1- month service use data as 
uninformative for participants who are missing data for the 
assessment period. These two sensitivity analyses explore the 
impact on the results of this approach.
Treatment received rather 
than intention- to- treat
 Ź The MCT group will only include 
those who attended at least one 
MCT session
The primary analysis will be an intention- to- treat approach. 
Recognising that not all patients assigned to the MCT 
intervention will attend, we will also run an analysis dividing the 
group using the recorded MCT attendance data.
Subgroup analyses  Ź History of anxiety and depression at 
baseline
 Ź Gender
 Ź HADS at baseline (severity of 
depression and anxiety)
Subgroup analysis will be conducted if there are enough 
numbers of participants in each group, to explore how the likely 
cost- effectiveness differs according to the population. Note, 
this is highly explorative and will be used to guide the economic 
model and generate further research questions rather than 
producing deinitive results/conclusions.
Measure of beneit  Ź Hospital Anxiety and Depression 
Scale (HADS)
 Ź Cases of anxiety and/or depression
 Ź Reliable improvement in HADS 
score
 Ź Return to productive activity
Secondary analyses will explore the cost- effectiveness of MCT 
intervention using a problem- speciic measure of effectiveness, 
rather than the generic QALY. This will look at the cost per point 
change in the HADS, as well as cost per reliable improvement 
in HADS and cost per case of anxiety and/or depression 
avoided. Cases of anxiety and depression will be classiied using 
the HADS score (8 to 10=mild, 11 to 14=moderate and 15 to 
21=severe).45 In our analysis we will focus on the cut- off used 
in the inclusion criteria for the Group MCT trial (≥8 on either the 
depression or anxiety subscale of the HADS). Productive activity 
(employed, voluntary work, in education or training, carer or 
looking after the family or home). These alternative measures 
of beneit will be used to aid decision- makers who may be less 
familiar with QALYs or have different objectives/targets.
Utility value set to estimate 
QALYs
 Ź Alternative EQ- 5D value sets (Devlin 
et al 201846; van Hout et al, 201220)
Secondary analyses will explore the impact of using alternative 
value sets to calculate QALYs. The primary analysis will use the 
value set recommended by NICE at the time of the analysis, the 
remaining EQ- 5D value set will be used in a sensitivity analysis. 
This will assess the impact of the different methods that can be 
used to estimate utility.
Cost of MCT intervention  Ź Assumed larger group size
 Ź Inclusion of wider costs (training 
and catering)
Sensitivity analysis will be conducted in which a larger average 
group size is assumed because if MCT was implemented in CR, 
a larger group size would be likely. Additionally, separately to 
group size, we will also look at a more comprehensive (although 
uncertain) method of costing the MCT intervention, which will 
include staff training costs
Continued
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The primary measure of interest for the economic anal-
ysis is the incremental cost- effectiveness ratio (ICER). 
Rather than considering cost and health benefit sepa-
rately, the ICER is a joint measure of both. It is calcu-
lated by dividing the difference in costs (net costs) by the 
difference in QALYs (net QALYs) between any two inter-
ventions. The ICER represents the additional cost of an 
intervention per additional QALY gained:
 
*$&3  $PTU .$5 JOUFSWFOUJPO QMVT VTVBM DBSF − $PTU VTVBM DBSF2"-:T .$5 JOUFSWFOUJPO QMVT VTVBM DBSF − 2"-:T VTVBM DBSF  
Note that if the intervention is cost saving and produces 
more QALYs when compared with usual care (ie, it falls 
in the South East quadrant of the cost- effectiveness 
plane), an ICER will not be presented as intervention is 
dominant in such a scenario. Likewise, if intervention is 
dominated (ICER lies in the North West quadrant of the 
cost- effectiveness plane) it will be described in this way 
rather than calculated and presented numerically.
Descriptive analysis and data manipulation will be 
conducted using SPSS V.25 and the main statistical anal-
yses will be conducted in Stata V.15.
Regression analysis will be used to estimate the net 
costs and QALYs of MCT. Cost and QALY data may not be 
normally distributed. Graphical summaries and descrip-
tive statistics will be used to assess the distribution of 
the pooled cost and QALY data and identify the appro-
priate regression models for the analysis (eg, generalised 
linear model with gamma, log distribution for costs). Key 
covariates will be included in the regression models to 
control for baseline factors that may influence costs or 
QALYs. The covariates for these analyses will be identified 
using the approach outlined for the multiple imputation 
described in the previous section.
The ICER measures the cost per QALY gained by an 
intervention which then raises the question of whether 
the additional cost of a QALY is worth paying for. To 
help address this, the ICER can be compared with bench-
mark or threshold values of how much decision- makers 
may be willing to pay to gain one additional QALY. This 
is analogous to placing a monetary value on one QALY. 
This then allows cost- effectiveness acceptability analysis, 
which is recommended by NICE for health technology 
appraisals.14
In the UK there is no universally agreed cost- effectiveness 
threshold value. One commonly reported threshold 
is from NICE in England of approximately £20 000 to 
£30 000 per QALY.29 However, there is a lack of consensus 
around the appropriate threshold and some argue that 
it has reduced as expenditure has been constrained.30–32 
Therefore, the monetary value of simulated QALYs will 
be varied from £0 to £30 000 to reflect a range of hypo-
thetical willingness to pay thresholds (WTPT).
Handling uncertainty
The estimates of costs and health benefits from the regres-
sion analyses will be bootstrapped to simulate 10 000 pairs 
of incremental cost and QALY outcomes of the MCT 
intervention.14 This captures the relationship between 
costs and QALYs. The pairs of net costs and QALYs will be 
plotted on a cost effectiveness plane to illustrate the level 
of uncertainty in the data.
Each of the net QALY estimates from bootstrap simu-
lation results can be revalued by multiplying it by a will-
ingness to pay threshold. Using these revalued QALY 
estimates it is then possible to estimate the net benefit 
statistic (NB) for each pair of simulated net costs and net 
benefits as:
NB = (O × threshold) – C, where O = net outcome score 
and C = net cost.
This process will be repeated for the WTPT values 
of interest to generate a cost effectiveness acceptability 
curve.
Additional sensitivity analysis will be used to test the 
impact of the study design on the ICER and results of the 
cost- effectiveness acceptability analysis. This will include 
subgroup analysis to estimate the impact of heterogeneity 
across the population, and scenario analysis to estimate 
the impact of study design on the cost- effectiveness of 
intervention. A detailed description of the likely sensi-
tivity analysis and rationale are described in table 2. Note 
that the sensitivity analysis is informed by data collected 
in the trial.
Long-term health economic model
A de novo economic model will be constructed using 
Microsoft Excel and programmed in Visual Basic for 
Applications. There are two key reasons for the develop-
ment of this model: (1) to explore the cost- effectiveness 
of MCT over a longer time horizon, and (2) to explore 
the cost- effectiveness of MCT in different populations 
and settings. The model design work will begin in April 
2020, targeted literature reviews to identify relevant data 
Assumptions/variables Changes Rationale
Time horizon  Ź 4 months The inal trial time follow- up is 12 months. A secondary analysis 
will consider the 4- month follow- up (the primary follow- up of the 
trial), to assess the impact of different follow- up periods on cost- 
effectiveness results.
Adherence to CR has been deined by the study team as the attendance to four or more sessions to each component of usual CR 
(exercise sessions and educational talks).
CR, cardiac rehabilitation; MCT, metacognitive therapy; QALY, quality- adjusted life- year.
Table 2 Continued
Protected by copyright.
 o
n
 Septem
ber 22, 2020 at The Librarian J B M
orrell Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035552 on 10 September 2020. Downloaded from 
7Shields GE, et al. BMJ Open 2020;10:e035552. doi:10.1136/bmjopen-2019-035552
Open access
will be performed in April and June 2020, with the model 
expected to be constructed and validated by September 
2020.
Model design and validation
The economic model structure will be developed from 
the trial care pathways and literature reviews of existing 
models for depression interventions in patients with and 
without comorbidities. Iterative, structured discussion 
with the wider trial team which includes clinical advisors 
for the project (including cardiac specialists and psychol-
ogists) will be used to assess the face validity of the struc-
ture and identify necessary amendments.
Once the model structure is drafted it will be discussed 
with an external Health Economics Adviser (part of the 
Trial Steering Committee) and the trial PPI group to 
assess whether it captures the key events and outcomes. 
An initial model structure has been drafted and will be 
used as a basis for discussion but may not reflect the final 
chosen model structure. The model structure will also be 
validated by using the trial data and follow- up data and 
assessing whether the results are within ±5% of the within 
trial economic analysis for the trial time horizon.
The literature discusses the many benefits of complex 
models, such as microsimulation models, which can 
incorporate patient heterogeneity and history, and can 
more closely reflect clinical pathways and time frames, 
such models are data hungry and computationally 
burdensome. Given that there is limited evidence (eg, 
over a long time frame) for MCT in CR, for the potential 
patient population (eg, history leading up to a cardiac 
event) and the population is likely to be heterogeneous, 
many assumptions would need to be made to apply a 
discrete event simulation methodology, likely leading to 
an ‘Occam’s razor’ scenario. A recent review found that 
Markov models are more common than other modelling 
methods when looking at mental health interventions.33 
Another recent review looking at model- based analyses 
specifically of treatments for depression found that the 
majority of papers used decision trees (21/41) or Markov 
models (15/41).34 Therefore, a simpler model design 
(decision tree and/or Markov) is likely to be preferred.
Identifying data sources
Data from the trial will likely inform the majority of short- 
term parameters within the base case economic model. 
This will be supplemented with structured literature 
reviews to identify parameters and alternative inputs 
for the short- term that might help to inform analyses in 
alternative settings and population. Examples of inputs 
that will be identified will include uptake rates in cardiac 
rehabilitation, utilities, costs, mortality and likelihood 
of depression/anxiety relapse and remission. Evidence 
relevant to the cardiac population will be prioritised. 
Parameter tables will be drafted and shared with the clin-
ical advisers on the project to discuss and assess clinical 
validity prior to use in the model. Data uncertainty will be 
explored in the sensitivity analysis outlined below.
Primary analysis
The model will report the estimated costs, QALYs 
and ICER for MCT plus usual care, versus usual care, 
with a 5- year time horizon. Costs and outcomes will be 
discounted at a rate of 3.5% in line with UK guidelines.14 
Probabilistic sensitivity analysis (PSA) will be performed, 
using Monte Carlo simulation with 10 000 iteration runs. 
The Monte Carlo simulation samples from the distribu-
tion of possible values for each parameter in the decision 
model so that mean costs and outcomes, and measures 
of variance (SD and 95th percentiles) can be estimated 
to assess the uncertainty inherent in the data used 
for the model. PSA results will be presented on a cost- 
effectiveness plane and cost- effectiveness acceptability 
curves will be produced, in line with NICE recommenda-
tions for health technology appraisals.14
Sensitivity analysis
Like the trial analysis, sensitivity analysis will be used to 
explore the impact of design choices on cost- effectiveness, 
as well as to consider potential longer- term outcomes. A 
detailed description of the likely sensitivity analysis and 
rationale are described in the online supplementary 
material. One of the key sensitivity analyses will be the 
investigation of the impact of different assumed dura-
tions of MCT effect. Details of the analysis will be refined 
following analysis of trial data and the review of wider 
literature and will be validated by clinicians. Note that the 
results for all sensitivity analysis will be run and reported 
in the same way as the primary analysis. Additionally, the 
model will also include one- way sensitivity analysis, varying 
parameters between their lower and upper bounds and 
presenting the results of this in a Tornado diagram.
DISCUSSION
This economic evaluation will comprehensively assess the 
potential cost- effectiveness of MCT for CR patients. Work 
will start with the economic evaluation integrated into the 
randomised controlled trial, prospectively designed to 
collect resource use and health outcome data in the trial 
participants. A robust within- trial economic evaluation 
will be conducted with a time horizon of 12- months. Pre- 
specified subgroup and sensitivity analyses will test the 
impact of design choices on the results and conclusions 
of the primary analysis. The economic evaluation work 
will be expanded with the design and construction of an 
economic model, intended to estimate the potential cost- 
effectiveness of MCT for CR over a longer time horizon, 
as well as investigating results across different settings and 
populations. To the team’s knowledge this will be the first 
economic evaluation of MCT. It will also add to the very 
limited economic evidence for psychological therapies 
within CR.6
The work will be published in peer reviewed journals 
and presented at economic and/or clinical focussed 
conferences. The PPI group from the group MCT trial will 
be presented with the findings of the economic evaluation 
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and consulted about possible dissemination activities that 
target patient groups. Published work will include discus-
sion on the limitations, generalisability of the evidence to 
setting outside of the UK and a comparison to the exiting 
wider evidence for the cost- effectiveness of CR. The latter 
will be identified from existing systematic reviews and 
more recently published work.6 35–39
There are a number of anticipated challenges of the work 
that may result in limitations associated with the economic 
evaluations. Regarding the within- trial analysis missing 
data poses a threat to economic evaluations. However, 
imputation methods are planned to reduce the impact 
of this and a complete- case analysis will be conducted as 
part of the scenario analysis.40 In addition, the final publi-
cation will report the potential impact of missing data, 
for example, summarising the level of missingness by data 
type. Nevertheless, the multiple imputation approach 
assumes that the data are missing at random (conditional 
on observed responses to clinical and economic measures 
and baseline covariates), which may not be valid. A high 
level of complete data on the primary clinical outcome, is 
anticipated, which may help to strengthen analysis based 
on the missing at random assumption. However, it may 
not be sufficient to account for systematic differences in 
costs and health benefits between participants with and 
without missing data or incomplete follow- up. Sensitivity 
analysis using (i) complete case analysis and (ii) a pattern 
mixture approach, which assumes compliance and clin-
ical outcomes are systematically worse in people with 
missing or with incomplete follow- up.26 28
Healthcare resource use will be self- reported by 
participants in the trial. The literature notes that self- 
report questionnaires are a valid approach to collecting 
healthcare resource use41 and were used in previous UK 
cost- effectiveness analyses of cardiac rehabilitation.42 43 
However, self- report forms are susceptible to recall bias 
and missing data. To improve feasibility and reduce bias, 
the service use questionnaire was adapted from those 
used in previous trials (references) and changes made 
jointly with service users and clinical experts. The forms 
were pilot- tested and refined. Service users complete the 
form at baseline by interview, to familiarise them with 
the forms. At follow- up, participants are also offered 
telephone assistance with completing the forms. Never-
theless, reliance on self- reported service use to estimate 
costs is a limitation of the economic analysis. It is not 
clear whether this will lead to systematic under or over 
reporting of costs and/or contribute to non- systematic 
inaccuracy of reported service use and costs.
Collecting some or all of the service use data from 
routinely collected electronic data sets in England was 
explored. Issues encountered included the need for 
secondary, primary, community and social care data for 
the study participants. Linked electronic data across 
these sectors is not typically available in England at local 
or national level. Ethical and governance approval and 
funding constraints meant it was beyond the scope of 
this study to identify all services used by participants, and 
review the case notes held by each service the participants 
used. Centrally collected databases in England, such as 
NHS Digital, typically do not include linked data for the 
range of services included in the study. This meant that 
the majority of service use data would need to be collected 
directly from participants.36 Access to hospital service use 
data for named patients via NHS Digital was paused and 
not available when the funding application was made. At 
the point at which the data collection methods needed 
to be finalised, the time to access data from NHS Digital 
was estimated at 12 months from the last participant 
completing the final scheduled follow- up to ensure the 
records were complete. Accordingly, while collecting 
service use data from participants is a limitation of the 
economic analysis, sourcing some or all of this data was 
not feasible within the funding and time constraints for 
this study.
The trial is being conducted in the North West of 
England; cardiac services and populations vary across 
the country, therefore there may be generalisability 
issues. In particular, the types of people offered CR is 
very broad and in some settings certain groups may be 
prioritised and attendance may vary.1 2 If possible, the 
economic modelling work will explore the potential cost- 
effectiveness of MCT in other settings and populations 
in an attempt to understand how this may vary. However, 
the variation across settings and populations is likely to 
reduce generalisability although decision- makers should 
consider whether the intervention and participants are 
reflective of their setting. As noted in the introduction, 
only around half of those offered CR in the UK attend 
and there is insufficient data available about the propor-
tion specific to those with symptoms of anxiety and/or 
depression.1 This analysis is limited to people who attend 
cardiac rehabilitation. Important questions remain 
around how to increase attendance and what methods 
would be cost- effective in doing so, which are outside 
of the scope of this analysis but should be addressed by 
future studies.
Multimorbidity is a complicating factor of the analysis 
and although we will attempt to understand and discuss 
how physical and mental health interact in this popula-
tion the data is likely to be limited, and it is likely that the 
model will focus on depression and anxiety. The devel-
opment of the economic model will require data from 
the wider published literature, but until searches are 
conducted it is not known how abundant and robust this 
data will be. Given the complexity of economic evaluation 
and the numerous possibilities for the economic model-
ling work, practical steps, such as reviewing the existing 
literature and discussions with clinical experts, will aim to 
ensure that the economic evaluations are as meaningful 
and useful in supporting decision- making as possible.
The discussed study will provide evidence on the poten-
tial cost- effectiveness of MCT in CR in the UK. This is 
highly relevant for decision- makers given the prevalence 
of depression and/or anxiety in the CR population, the 
economic and health burden associated with both cardiac 
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problems and depression and/or anxiety and calls for 
more integration of physical and mental health services.44
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